Search

Multispectral compatible stealth encounters higher challenges and requirements with the combined application of multiple detection technologies. This paper proposes a multilayer film based on thin-film interference and impedance matching to achieve 1.06 µm and 1.54 µm dual-laser stealth and mid-wavelength infrared (MWIR, 3–5 µm) and long-wavelength infrared (LWIR, 8–14 µm) stealth, as well as thermal management by the non-atmospheric window (5–8 µm). The multilayer film consists of Al 2 O 3 , Fe 3 O 4 , ZnS, Ge and Ag layer (Al 2 O 3 /ZnS/Ge/Ag/Fe 3 O 4 /Ag) and the optical performance of multilayer film is calculated using the finite-difference time-domain (FDTD) method. The numerical results indicated that the spectral emissivity of the multilayer film is lower than 27 % in the MWIR and 14 % in the LWIR and the spectral absorptances are both over 98 % at the laser wavelength 1.06 µm and 1.54 µm, respectively, as well as in the non-atmospheric window. Moreover, the optical performance of the multilayer film could be influenced with incident angle whether it is TM or TE wave but independent of the polarization angle. This work provides theoretical guidance for design and optimization of multilayer film that processes the compatibility of infrared stealth in the MWIR and LWIR and dual-laser stealth with thermal management in the non-atmospheric windows. [ABSTRACT FROM AUTHOR]

OBJECTIVE: The aim of this study is to compare surgery with adjuvant chemoradiotherapy versus non-surgical treatments for patients with early-stage small cell lung cancer (SCLC) based on the short-term and long-term efficacy. METHODS: SCLC patients who underwent a pulmonary lobectomy with post-surgical radiotherapy or chemotherapy were assigned to the surgical group. SCLC patients who received radiotherapy or chemotherapy alone were classified into the nonsurgical group. The clinical efficacy was evaluated as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD). The total effectiveness rate was calculated as CR + PR. The 1-, 3-, and 5-year survival rates of the two groups were compared. RESULTS: Compared with the non-surgical group, the CR rate and the total effectiveness rate were higher in the surgical group, and the total effectiveness rate for male patients and patients without a smoking history were also higher in the surgical group. Distant metastasis and local recurrence concurrent with distant metastasis in the surgical group were both lower in the surgical group than in the non-surgical group. Compared with the non-surgical group, the local recurrence in male patients was lower in the surgical group, and patients in the surgical group had lower distant metastasis at TNM stage IIb. The 1-, 3-, and 5-year survival rates were higher in the surgical group than in the non-surgical group. CONCLUSIONS: These findings indicate that for patients with early-stage SCLC, better scores in effectiveness rate, disease progression, and 1-, 3-, and 5-year survival rates were observed in patients who underwent surgery followed by adjuvant chemoradiotherapy when compared with patients without surgical treatment. [ABSTRACT FROM AUTHOR]